Expanded Access Protocol (Eap) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming

Recruiting

18-99 years

All

Phase N/A

1 Location

Brief description of study

This study is designed to provide patients access to their nonconforming ide-cel as a treatment option for their disease. The study will evaluate the safety and effectiveness of this therapy through the collection of information. You may or may not receive direct medical benefit from participating in this study. The hope is that this study treatment may provide a new treatment option for patients with your disease, however, such a benefit cannot be guaranteed. There are no study specific procedures required for this study as you will receive routine medical care during the course of your participation. Results from these routine medical care procedures will be collected for research purposes.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
multiple myeloma
Age: Between 18 Years - 99 Years
Gender: All

Male or Female, Age 18 or older, multiple myeloma has had idecabtagene vicleucel (ide-cel), for the treatment of your disease as part of routine care

Updated on 09 Mar 2024. Study ID: 849169

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).